10 November 2016

Background document for sodium peroxometaborate

Document developed in the context of ECHA's seventh Recommendation for the inclusion of substances in Annex XIV

ECHA is required to regularly prioritise the substances from the Candidate List and to submit to the European Commission recommendations of substances that should be subject to authorisation. This document provides background information on the prioritisation of the substance, as well as on the determination of its draft entry in the Authorisation List (Annex XIV of the REACH Regulation). Information comprising confidential comments submitted during public consultation(s), or relating to content of registration dossiers which is of such nature that it may potentially harm the commercial interest of companies if it was disclosed, is provided in a confidential annex to this document.

Information relevant for prioritisation and/or for proposing Annex XIV entries provided during the public consultation on the inclusion of sodium peroxometaborate on the authorisation list or in the registration dossiers (as of the last day of the public consultation, i.e. 18 February 2016) was taken into consideration when finalising the recommendation and is reflected in the present document.

The background document also describes how ECHA has taken into account the MSC opinion.

Contents

1. Identity of the substance

Chemical name:	Sodium peroxometaborate
EC Number:	231-556-4
CAS Number:	7632-04-4
IUPAC Name:	Sodium peroxometaborate

2. Background information for prioritisation

Priority was assessed by using the General approach for prioritisation of SVHCs for inclusion in the list of substances subject to authorisation[1]. Results of the prioritisation of all substances included in the Candidate List by June 2014 and not yet included or recommended in Annex XIV of the REACH Regulation is available at *http://echa.europa.eu/documents/10162/13640/prioritisation_results_CL_substances_nov_2015_en.pdf*.

The prioritisation results of the substances included in the draft 7th recommendation have been updated as necessary after the public consultation. The updated results are available at https://echa.europa.eu/documents/10162/13640/prioritisation_results_draft7threc_substances_feb2016_en.pdf.

2.1. Intrinsic properties

Sodium peroxometaborate was identified as a Substance of Very High Concern (SVHC) according to Article 57 (c) as it is classified in Annex VI, part 3, Table 3.1 (the list of harmonised classification and labelling of hazardous substances) of Regulation (EC) No 1272/2008 as Toxic for Reproduction, Category 1B (H360Df: "May damage the unborn child. Suspected of damaging fertility"), and was therefore included in the Candidate List for authorisation on 16 June 2014, following ECHA's decision ED/49/2014.

2.2. Volume used in the scope of authorisation

There are no registrations for sodium peroxometaborate under Regulation (EC) No 1907/2006 (REACH)[2].

2.3. Wide-dispersiveness of uses

There are no registrations for sodium peroxometaborate under Regulation (EC) No 1907/2006 (REACH).

During the public consultation to identify sodium peroxometaborate as SVHC (RCOM, 2014) comments were received indicating the use of the substance as laboratory chemical in scientific research and development (SRD), however this use appears to be outside the scope of authorisation.

Some more information on uses of "perboric acid, sodium salt (PBS)" which covers also

[1] Document can be accessed at http://echa.europa.eu/documents/10162/13640/gen_approach_svhc_prior_in_recommendations_en.pdf
[2] Number of registrations as of 18 February 2016

EC 231-556-4 is provided in Annex I.

2.4. Further considerations for priority setting

Based on structural similarities it appears that sodium peroxometaborate could potentially replace another perborate compound in the Candidate List: sodium perborate; perboric acid, sodium salt. Although sodium peroxometaborate is currently not registered, there is the potential that both substances could be used in similar applications.

2.5. Conclusion

Sodium peroxometaborate is **recommended for inclusion in Annex XIV** based on grouping considerations.

3. Background information for the proposed Annex XIV entry

Draft Annex XIV entries were determined on the basis of the General approach for preparation of draft Annex XIV entries for substances to be included in Annex XIV[3]. The draft Annex XIV entries that underwent public consultation are available at:
http://echa.europa.eu/documents/10162/13640/7th_recom_draft_axiv_entries_en.pdf .

The final draft Annex XIV entries that ECHA recommends are available at:
https://echa.europa.eu/documents/10162/13640/7th_axiv_recommendation_november2016_en.pdf.

3.1. Latest application and sunset dates

The LAD slots are set in 3-month intervals (normally 18, 21 and 24 months after inclusion in Annex XIV but more slots can be considered on a case-by-case basis). In its draft recommendation ECHA had seen no reason to deviate from the three LAD slots of 18, 21 and 24 months after inclusion in Annex XIV that are normally assigned in a recommendation. Sodium peroxometaborate had been considered to be placed in the same slot with sodium perborate; perboric acid, sodium salt in the draft recommendation. These two perborates compounds were assigned to the 2nd LAD slot. As the number of different uses seems limited, it was assumed that the preparation of an application for authorisation may require less time when compared with the lead compounds (that were proposed to be placed in the 3rd slot) due to their higher (overall) supply chain complexity.

[3] Document can be accessed at
http://echa.europa.eu/documents/10162/13640/recom_general_approach_draft_axiv_entries.pdf

During the public consultation no comments were received that challenged the proposed transitional arrangements.

ECHA recommends the following transitional arrangements:

Latest application date (LAD):	Date of inclusion in Annex XIV plus **21 months**
Sunset date (SSD):	18 months after LAD

3.2. Review period for certain uses

In its draft recommendation ECHA had seen no ground to include in Annex XIV any review period.

During the public consultation ECHA did not receive comments requesting upfront review period for certain uses.

ECHA therefore **does not propose to include in Annex XIV any review period** for sodium peroxometaborate.

3.3. Uses or categories of uses exempted from authorisation requirement

3.3.1. Exemption under Article 58(2)

In its draft recommendation, ECHA had not proposed any exemption for (categories of) uses of sodium peroxometaborate on the basis of Article 58(1)(e) in combination with Article 58(2) of the REACH Regulation.

During the public consultation ECHA did not receive requests for exemptions under Article 58(2).

ECHA therefore **does not recommend exemptions for uses** of sodium peroxometaborate on the basis of Article 58 (1)(e) in combination with **Article 58(2)** of the REACH Regulation.

3.3.2. Exemption of product and process oriented research and development (PPORD)

In its draft recommendation ECHA had not proposed to include in Annex XIV any exemption from authorisation for the use of sodium peroxometaborate for PPORD.

During the public consultation ECHA did not receive requests for such type of exemption.

ECHA therefore **does not recommend exempting any use** of sodium peroxometaborate for **PPORD** from authorisation.

4. References

Annex XV report (2014): Proposal for identification of a substance as a CMR Cat 1A or 1B, PBT, vPvB or a substance of an equivalent level of concern. Sodium peroxometaborate. Submitted by Denmark, March 2014.

http://echa.europa.eu/documents/10162/74778154-75a8-428e-adad-0516a1189da7

RCOM (2014): "*Responses to comments*" document. Document compiled by Denmark from the commenting period 03/03/2014 - 17/04/2014 on the proposal to identify sodium peroxometaborate as a Substance of Very High Concern.

http://echa.europa.eu/candidate-list-table/-/substance-rev/2370/del/200/col/staticField_-104/type/desc/pre/1/view

ANNEX I: Further information on uses

Sodium peroxometaborate has not been registered under REACH4.

According to the Annex XV report (2014), perboric acid, sodium salt (PBS)5 is used in chemical mixtures for bleaching and cleaning agents. According to AISE (International Association for Soaps, Detergents and Maintenance Products), 96% of the PBS used in detergent products in 1999 was used in heavy duty bleach-containing powders or tablets, and 3% in machine dishwashing detergents (powders or tablets). Further uses mentioned are denture cleansers and stain removers. According to the Annex XV report (2014) the concentrations of PBS in the detergents products and in bleaching agents are between 4-25% and 5-50%, respectively.

[4] as of 18 February 2016
[5] Part II of the Annex XV report (2014) refers to "perboric acid, sodium salt (PBS)" which covers the following EC numbers: 239-172-9, 234-390-0, 231-556-4.